- Home
- MBIO vs KTTA Comparison
MBIO vs KTTA Comparison
Compare MBIO & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- KTTA
- Stock Information
- Founded
- MBIO 2015
- KTTA 2020
- Country
- MBIO United States
- KTTA United States
- Employees
- MBIO N/A
- KTTA N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- MBIO Health Care
- KTTA Health Care
- Exchange
- MBIO Nasdaq
- KTTA Nasdaq
- Market Cap
- MBIO 4.7M
- KTTA 5.1M
- IPO Year
- MBIO N/A
- KTTA 2021
- Fundamental
- Price
- MBIO $1.43
- KTTA $0.79
- Analyst Decision
- MBIO
- KTTA
- Analyst Count
- MBIO 0
- KTTA 0
- Target Price
- MBIO N/A
- KTTA N/A
- AVG Volume (30 Days)
- MBIO 147.7K
- KTTA 178.0K
- Earning Date
- MBIO 11-07-2025
- KTTA 08-14-2025
- Dividend Yield
- MBIO N/A
- KTTA N/A
- EPS Growth
- MBIO N/A
- KTTA N/A
- EPS
- MBIO N/A
- KTTA N/A
- Revenue
- MBIO N/A
- KTTA N/A
- Revenue This Year
- MBIO N/A
- KTTA N/A
- Revenue Next Year
- MBIO N/A
- KTTA N/A
- P/E Ratio
- MBIO N/A
- KTTA N/A
- Revenue Growth
- MBIO N/A
- KTTA N/A
- 52 Week Low
- MBIO $0.89
- KTTA $0.65
- 52 Week High
- MBIO $21.95
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- MBIO 39.31
- KTTA 54.58
- Support Level
- MBIO $1.51
- KTTA $0.75
- Resistance Level
- MBIO $1.59
- KTTA $0.91
- Average True Range (ATR)
- MBIO 0.09
- KTTA 0.06
- MACD
- MBIO -0.01
- KTTA 0.01
- Stochastic Oscillator
- MBIO 2.89
- KTTA 45.79
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).